Intra-Arterial Rhenium-188 Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results of an IAEA-Sponsored Multination Study.

Intra-Arterial Rhenium-188 Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results of an IAEA-Sponsored Multination Study. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Intra-Arterial Rhenium-188 Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results of an IAEA-Sponsored Multination Study. Abstract Text:

Patricia Bernal,Jean-Luc Raoul,Gaj Vidmar,Erdenechimeg Sereegotov,Felix X Sundram,Ajay Kumar,Jae Min Jeong,Pawana Pusuwan,Chaitanya Divgi,Pat Zanzonico,Janez Stare,John Buscombe,Chau Trinh Thi Minh,Maung Maung Saw,Shaoliang Chen,Ruben Ogbac,Ajit K Padhy,Patricia Bernal,Jean-Luc Raoul,Gaj Vidmar,Erdenechimeg Sereegotov,Felix X Sundram,Ajay Kumar,Jae Min Jeong,Pawana Pusuwan,Chaitanya Divgi,Pat Zanzonico,Janez Stare,John Buscombe,Chau Trinh Thi Minh,Maung Maung Saw,Shaoliang Chen,Ruben Ogbac,Ajit K Padhy,Patricia Bernal,Jean-Luc Raoul,Gaj Vidmar,Erdenechimeg Sereegotov,Felix X Sundram,Ajay Kumar,Jae Min Jeong,Pawana Pusuwan,Chaitanya Divgi,Pat Zanzonico,Janez Stare,John Buscombe,Chau Trinh Thi Minh,Maung Maung Saw,Shaoliang Chen,Ruben Ogbac,Ajit K Padhy,

PURPOSE: Intra-arterial injections (IAI) of 131I-lipiodol is effective in treating hepatocellular carcinoma patients, but is expensive and requires a 7-day hospitalization in a radioprotection room. 188Re is inexpensive, requires no patient isolation, and can be used with lipiodol. METHODS AND MATERIALS: This International Atomic Energy Agency-sponsored phase II trial aimed to assess the safety and the efficacy of a radioconjugate 188Re + lipiodol (188Re-Lip) in a large cohort of hepatocellular carcinoma patients from developing countries. A scout dose is used to determine the maximal tolerated dose (lungs <12 Gy, normal liver <30 Gy, bone marrow <1.5 Gy) and then the delivery of the calculated activity. Efficacy was assessed using response evaluation criteria in solid tumor (RECIST) and alpha-feto-protein (alphaFP) levels and severe adverse events were graded using the Common Toxicity Criteria of the National Cancer Institute scale v2.0. RESULTS: The trial included 185 patients from eight countries. The procedure was feasible in all participating centers. One treatment was given to 134 patients; 42, 8, and 1 received two, three, and four injections, respectively. The injected activity during the first treatment was 100 mCi. Tolerance was excellent. We observed three complete responses and 19 partial responses (22% of evaluable patients, 95% confidence interval 16-35%); 1- and 2-year survivals were 46% and 23%. Some factors affected survival: country of origin, existence of a cirrhosis, Cancer of the Liver Italian Program score, tumor dose, absence of progression, and posttreatment decrease in alphaFP level. CONCLUSIONS: IAI of 188Re-Lip in developing countries is feasible, safe, cost-effective, and deserves a phase III trial.

Intra-Arterial Rhenium-188 Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results of an IAEA-Sponsored Multination Study. Publishing Authors By Initials

P Bernal,JL Raoul,G Vidmar,E Sereegotov,FX Sundram,A Kumar,JM Jeong,P Pusuwan,C Divgi,P Zanzonico,J Stare,J Buscombe,CT Minh,MM Saw,S Chen,R Ogbac,AK Padhy,P Bernal,JL Raoul,G Vidmar,E Sereegotov,FX Sundram,A Kumar,JM Jeong,P Pusuwan,C Divgi,P Zanzonico,J Stare,J Buscombe,CT Minh,MM Saw,S Chen,R Ogbac,AK Padhy,P Bernal,JL Raoul,G Vidmar,E Sereegotov,FX Sundram,A Kumar,JM Jeong,P Pusuwan,C Divgi,P Zanzonico,J Stare,J Buscombe,CT Minh,MM Saw,S Chen,R Ogbac,AK Padhy,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Intra-Arterial Rhenium-188 Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results of an IAEA-Sponsored Multination Study. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: International journal of radiation oncology, biolo

VOLUME: 69

Page Numbers: 1448-55

Journal Abbreviation: Int. J. Radiat. Oncol. Biol. P

ISSN: 0360-3016

DAY: 9

MONTH: 08

YEAR: 2007

Intra-Arterial Rhenium-188 Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results of an IAEA-Sponsored Multination Study. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7603616

Intra-Arterial Rhenium-188 Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results of an IAEA-Sponsored Multination Study. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Intra-Arterial Rhenium-188 Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results of an IAEA-Sponsored Multination Study. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Intra-Arterial Rhenium-188 Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results of an IAEA-Sponsored Multination Study.

AFFILIATION: Fundacion Santa Fe De Bogota, Bogota, Colombia.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Int J Radiat Oncol Biol Phys

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Intra-Arterial Rhenium-188 Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results of an IAEA-Sponsored Multination Study Related Publications

• Assessment of Intra-urban Variability in Outdoor Air Quality and its Health Risks.
• Growth, yield and elemental status of rice (Oryza sativa) grown in fly ash amended soils.
• International atomic energy agency-sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study.
• Intra-Arterial Rhenium-188 Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results of an IAEA-Sponsored Multination Study.